Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Abstract

Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.

Keywords

• COVID‐19
• favipiravir
• ferritin
• Lopinavir
• lymphocytopenia
• ritonavir